Seres Therapeutics (MCRB) Misses Q2 EPS by 16c

Seres Therapeutics (NASDAQ: MCRB) reported Q2 EPS of ($0.53), $0.16 worse than the analyst estimate of ($0.37). Revenue for the quarter came in at $5.26 million versus the consensus estimate of $5.34 million.

For earnings history and earnings-related data on Seres Therapeutics (MCRB) click here.

You May Also Be Interested In

• Brunswick (BC) Reports In-Line Q1 EPS, provides guidance
• WNS Holdings (WNS) Tops Q4 EPS by 6c, provides guidance
• Applied Industrial Technologies (AIT) Tops Q3 EPS by 8c; Updates outlook